ROCKVILLE, Md. (AP) — Shares of Supernus Pharmaceuticals Inc. more than doubled in price Tuesday after the specialty drugmaker said regulators have moved closer to granting final approval to its potential epilepsy treatment Trokendi XR.
The Rockville, Md., company said the Food and Drug Administration gave tentative approval for the once-daily treatment and told Supernus it would require no additional clinical trials.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.